Jon A. Olson
Analyst · Goldman Sachs
Thank you, Rick. Xilinx sales were $511.1 million in the December quarter, a decrease of 8% sequentially and 10% on a year-over-year basis. This was slightly better than the revised guidance we provided on December 19, due primarily to increased business from large communication customers in Asia-Pacific and North America during the last 2 weeks of the quarter. Gross margin was 65.8%, up from 63.9% in the prior quarter and better than anticipated, driven primarily by favorable customer mix and continued overall cost reduction. Operating expenses were $199 million, flat with the prior quarter and a little less than guided, primarily due to lower variable expenses associated with lower revenue and increased attention to fiscal discipline. Operating margin was 26.8% for the quarter. New product sales decreased 13% sequentially and increased 5% on a year-over-year basis. Virtex-6, Spartan-6 and our 28-nanometer product families all posted solid sales growth during the quarter. The new product category, however, was impacted by declines from our Virtex-5 customers in the wireless segment. Mainstream products declined 1% sequentially, and base products were flat. Let me now turn to a discussion of end markets. In the face of a continued weak wireless demand environment, communication sales declined 10% sequentially, more than we were anticipating heading into the quarter. Wired communications, on the other hand, increased during the quarter with particular strength from enterprise networking. The industrial and other category was down, as expected, with sales decreasing 7% sequentially, driven by industrial, scientific and medical and test and measurement applications. Consumer and automotive sales were weaker than anticipated during the quarter, driven by declines from audio/video broadcast, consumer and automotive applications. Data processing sales were approximately flat. Net income for the quarter was $127 million or $0.47 per diluted share. Other income and expense was a net expense of $7.2 million. Third quarter net income included a tax benefit of $15.3 million or $0.06 per diluted share related to one-time items, including the lapse of the statute of limitations with respect to certain previously unrecognized tax positions. Operating cash flow for the September quarter was $181 million before $19 million in CapEx. For the past 4 quarters, cash generation from operations was $863 million, a new company record. We paid $50 million in cash dividends and repurchased 1.1 million shares of stock during the quarter for $32.5 million. The tax rate in the December quarter was 2%. Diluted shares for the quarter were 268 million. There was a 2.5 million share dilutive effect from our convertible notes due to an increase in the average stock price during the quarter. For questions relating to the dilution associated with our convertibles, please visit our Investor Relations website at www.investor.xilinx.com. Let me now comment on the balance sheet. Cash and investments increased $95 million to approximately $3.0 billion. We have approximately $1.3 billion in convertible debt, and our net cash position is approximately $1.7 billion. Days sales outstanding increased 3 days in December quarter to 38 days. Inventory dollars at Xilinx declined by $2.2 million sequentially during the quarter. Combined inventory days, both at Xilinx and distribution were 142 days, up from 126 days in the prior quarter. In the March quarter, we expect both dollars and days of inventory to decline significantly as we realign our supply with the demand trends. Let me now turn to a discussion of guidance for the March quarter of fiscal year '12. Our backlog heading into the quarter is up sequentially. We are expecting strong growth from our 28-nanometer and 40-nanometer product families. From an end-market perspective, we are expecting sales from communications to be up slightly sequentially, with wireless up modestly after a weak December quarter and wireline sales approximately flat. We expect industrial and other sales to increase as normal spending patterns return to many of our customers following 2 quarters of inventory drain. Additionally, we are expecting defense sales to increase during the quarter, driven in part by last time buy activity, but more significantly by the commencement of a large program. Consumer sales are expected to be approximately flat, and data processing sales are expected to decrease sequentially. As a result, we are expecting total sales to be up 2% to up 6% sequentially, with sales from Europe expected to increase, sales from Asia-Pacific expected to decrease and sales from North America and Japan to be approximately flat. The midpoint of our sales guidance is predicated on a turns rate of approximately 55%. Gross margin is expected to be between 64% and 65% as we absorb new product ramp costs and customer mix returns to normal historical levels. Operating expenses in the March quarter are expected to be approximately $207 million, including approximately $2 million of amortization of acquisition-related intangibles. The majority of the growth in spending compared with the December quarter is in R&D and related to the 28-nanometer ramp as our tape-out activity remains high. There's also some growth in SG&A related primarily to variable spending increases as result of higher revenue and growth in some key marketing and sales programs. The full year spending number is approximately $810 million, lower than our previous estimate of $820 million to $830 million. We will provide fiscal year 2013 guidance at our upcoming Analyst Meeting on February 15 in San Francisco. Other income and expense is expected to be a net expense of approximately $10 million. The share count is expected to be approximately 270 million shares, and the tax rate is expected to be approximately 14%. Let me now turn the call over to Moshe.